Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma

The high recurrence rate and dismal prognosis of localized intrahepatic cholangiocarcinoma (ICC) indicate the unmet need for effective adjuvant and neoadjuvant therapy. In recent years, progress has been made in immunotherapy and targeted therapy for the treatment of advanced biliary tract cancer (B...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuan Cheng, Xiangcheng Li
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024173872
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832573133676085248
author Yuan Cheng
Xiangcheng Li
author_facet Yuan Cheng
Xiangcheng Li
author_sort Yuan Cheng
collection DOAJ
description The high recurrence rate and dismal prognosis of localized intrahepatic cholangiocarcinoma (ICC) indicate the unmet need for effective adjuvant and neoadjuvant therapy. In recent years, progress has been made in immunotherapy and targeted therapy for the treatment of advanced biliary tract cancer (BTC), leading to clinical exploration of the provision of these therapies in the perioperative period. Based on years of experience in clinical research on hepatobiliary cancers, the authors discuss the design of studies on neoadjuvant therapy for ICC, aiming to provide references for future neoadjuvant studies.
format Article
id doaj-art-3016f79617bb48cb80c993901b1365cb
institution Kabale University
issn 2405-8440
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series Heliyon
spelling doaj-art-3016f79617bb48cb80c993901b1365cb2025-02-02T05:27:47ZengElsevierHeliyon2405-84402025-01-01112e41356Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinomaYuan Cheng0Xiangcheng Li1Department of Medical Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210002, ChinaHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China; Corresponding author.The high recurrence rate and dismal prognosis of localized intrahepatic cholangiocarcinoma (ICC) indicate the unmet need for effective adjuvant and neoadjuvant therapy. In recent years, progress has been made in immunotherapy and targeted therapy for the treatment of advanced biliary tract cancer (BTC), leading to clinical exploration of the provision of these therapies in the perioperative period. Based on years of experience in clinical research on hepatobiliary cancers, the authors discuss the design of studies on neoadjuvant therapy for ICC, aiming to provide references for future neoadjuvant studies.http://www.sciencedirect.com/science/article/pii/S2405844024173872CholangiocarcinomaNeoadjuvantImmunotherapyTargeted therapyDesigns
spellingShingle Yuan Cheng
Xiangcheng Li
Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma
Heliyon
Cholangiocarcinoma
Neoadjuvant
Immunotherapy
Targeted therapy
Designs
title Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma
title_full Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma
title_fullStr Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma
title_full_unstemmed Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma
title_short Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma
title_sort design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma
topic Cholangiocarcinoma
Neoadjuvant
Immunotherapy
Targeted therapy
Designs
url http://www.sciencedirect.com/science/article/pii/S2405844024173872
work_keys_str_mv AT yuancheng designofstudiesonneoadjuvanttherapyforintrahepaticcholangiocarcinoma
AT xiangchengli designofstudiesonneoadjuvanttherapyforintrahepaticcholangiocarcinoma